Neurocrine
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.
NBIX Key Statistics
Stock Snapshot
As of today, Neurocrine(NBIX) shares are valued at $152.37. The company's market cap stands at 15.19B, with a P/E ratio of 36.39.
During the trading session on 2025-11-08, Neurocrine(NBIX) shares reached a daily high of $154.25 and a low of $148.98. At a current price of $152.37, the stock is +2.3% higher than the low and still -1.2% under the high.
Trading volume for Neurocrine(NBIX) stock has reached 1.41M, versus its average volume of 1.44M.
The stock's 52-week range extends from a low of $84.23 to a high of $157.67.
The stock's 52-week range extends from a low of $84.23 to a high of $157.67.
NBIX News
Neurocrine Biosciences reported third quarter 2025 earnings, showing revenue of US$794.9 million and net income of US$209.5 million, both up from the same perio...
JPMorgan analyst Anupam Rama raised the firm’s price target on Neurocrine (NBIX) to $179 from $171 and keeps an Overweight rating on the shares. Elevate Your I...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...